Darunavir

Generic Name
Darunavir
Brand Names
Prezcobix, Prezista, Rezolsta, Darunavir Viatris (previously Darunavir Mylan), Darunavir Krka
Drug Type
Small Molecule
Chemical Formula
C27H37N3O7S
CAS Number
206361-99-1
Unique Ingredient Identifier
YO603Y8113
Background

Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy. It was initially approved by the FDA in 2006.
...

Indication

Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

First Posted Date
2015-07-21
Last Posted Date
2017-02-02
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
7
Registration Number
NCT02503462
Locations
🇨🇭

Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

First Posted Date
2015-07-03
Last Posted Date
2018-10-04
Lead Sponsor
Viriom
Target Recruit Count
24
Registration Number
NCT02489487
Locations
🇹🇭

Faculty of Medicine, Siriraj Hospital, Bangkok, Wanglang Road, Thailand

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

First Posted Date
2015-06-19
Last Posted Date
2023-06-22
Lead Sponsor
SEARCH Research Foundation
Target Recruit Count
15
Registration Number
NCT02475915
Locations
🇹🇭

SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

First Posted Date
2015-06-12
Last Posted Date
2016-06-30
Lead Sponsor
Juan A. Arnaiz
Target Recruit Count
150
Registration Number
NCT02470650
Locations
🇪🇸

Josep Mallolas Masferrer, Barcelona, Spain

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

First Posted Date
2015-05-07
Last Posted Date
2024-01-09
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
122
Registration Number
NCT02437110
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-03-10
Last Posted Date
2017-01-24
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
100
Registration Number
NCT02384967
Locations
🇫🇷

Hôpital Saint Louis, Paris, France

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

First Posted Date
2014-10-29
Last Posted Date
2018-01-24
Lead Sponsor
ViiV Healthcare
Target Recruit Count
32
Registration Number
NCT02277600
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

First Posted Date
2014-10-27
Last Posted Date
2024-10-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
769
Registration Number
NCT02275780
© Copyright 2024. All Rights Reserved by MedPath